Mark de Souza

FIBRX Derm, Inc. develops anti-scarring therapeutic for patients with Dystrophic Epidermolysis Bullosa. The company was founded by Mark de Souza, James W. Fordyce and Erkki Ruoslahti and is headquartered in Berkeley, CA.

SeylanMED LLC operates as a private biopharmaceutical company that develops a targeted therapy for Seborrheic Keratosis. The company as founded by Victor Neel and Anna Mandinova and is headquartered in Berkeley, CA.

Chromaderm, Inc. operates as a clinical stage biotech company. It develops topical PKC-beta inhibitor. The company was founded by Barbara A. Gilchrest, Mark de Souza and James W. Fordyce and is headquartered in Cambridge, MA.

SonALAsense, Inc. provides ALA Sonodynamic Therapy for the treatment of Glioblastoma Multiforme. The company was founded by Stuart Marcus and is headquartered in Berkeley, CA.

SeylanMED, Inc. engages in the development of topical akt inhibitor as a treatment for seborrheic keratosis. The company was founded by Victor Neel and Anna Mandinova and is headquartered in Berkeley, CA.

Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell.

NFlection Therapeutics, Inc. operates as a biotechnology company. It focuses on the development of therapies for Neurofibromatosis. The company was founded by Mark de Souza and Michael Wootton in 2014 and is headquartered in Wayne, PA.

NF2 Therapeutics, Inc. develops therapies. The American company was founded by Michael Wootton, Mark P de Souza, Scott Plotkin. Michael Wootton has been the CEO since incorporation.

Wings Therapeutics, Inc. engages in the development of transformational therapies for patients that suffer from Dystrophic Epidermolysis Bullosa. The company was founded in 2019 and is headquartered in Berkeley, CA.